Experimental brain cancer drug shows promise in early trial
NCT ID NCT03107780
First seen Nov 14, 2025 · Last updated May 08, 2026 · Updated 22 times
Summary
This early-phase trial tested a drug called navtemadlin (AMG 232) in people with glioblastoma, a serious brain cancer. The study had two parts: one measured how much drug reached brain tumors in patients whose cancer had returned, and the other combined the drug with radiation in newly diagnosed patients. The trial was stopped early, but the goal was to find the best dose and check safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
-
UPMC-Shadyside Hospital
Pittsburgh, Pennsylvania, 15232, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.